Cenobamate is used for the treatment of partial-onset seizures in adults, and standardized medication use is the key to ensuring efficacy and safety.

I. Dosage, Administration, and Titration Principles

1. Recommended Dosing Regimen

The starting dose is 12.5 mg once daily.

Titrate gradually according to a fixed schedule, with a final maintenance dose of 200 mg daily.

The maximum dose is 400 mg daily, which should be adjusted based on efficacy and tolerability.

2. Strictly Follow Titration Speed

Do not accelerate the dose increase rate without authorization; rapid titration may increase the risk of serious adverse reactions.

Adjust the dose every two weeks until the target dose is reached.

3. Administration Method

Once daily, can be taken with or without food.

Swallow whole, do not crush or chew.

It is recommended to take the medication at a fixed time to reduce missed doses.

4. Missed Doses and Discontinuation

If a dose is missed, consult a doctor on how to handle it; do not take a double dose on your own.

Do not stop the medication abruptly; it should be gradually tapered over at least 2 weeks.

Sudden discontinuation may induce status epilepticus.

II. Drug Interactions and Combination Therapy

1. Effects on Other Antiepileptic Drugs

When used concomitantly with phenytoin, phenytoin blood concentration increases, and its dose needs to be gradually reduced by up to 50%.

When used concomitantly with phenobarbital or clobazam, a reduction in their dosage may be necessary.

When used concomitantly with lamotrigine or carbamazepine, an increase in their dosage may be necessary.

2. Effects on CYP Substrates

When used concomitantly with CYP2B6 and CYP3A substrates, an increase in substrate dosage may be necessary.

When used concomitantly with CYP2C19 substrates, a decrease in substrate dosage may be necessary.

3. Oral Contraceptives

Cenobamate may reduce the effectiveness of oral contraceptives.

Women of childbearing potential should add or switch to non-hormonal contraceptive methods.

4. Central Nervous System Depressants and Alcohol

Concomitant use with alcohol or other central nervous system depressants may increase drowsiness and sedation.

Avoid drinking alcohol or use with caution during treatment.

III. Special Populations and Safety Monitoring

1. Hepatic and Renal Impairment

For patients with mild-to-moderate hepatic impairment, the maximum dose is 200 mg daily; severe hepatic impairment is not recommended.

Patients with mild, moderate, and severe renal impairment should use with caution, and dose reduction may be required.

End-stage renal disease patients on dialysis are not recommended to use.

2. Pregnancy and Lactation

Data on pregnant women is insufficient, and animal studies suggest potential harm to the fetus.

Patients planning pregnancy or already pregnant should inform their doctor and consider enrolling in a pregnancy registry.

It is unknown whether it passes into breast milk; breastfeeding women should consult a doctor.

3. Elderly Patients

Elderly patients should use the medication with caution, usually starting from a low dose.

Attention should be paid to liver, kidney, and heart functions, as well as concurrent medications.

4. Daily Safety Reminders

Avoid driving or operating machinery during the initial period of treatment until the drug's effects are clear.

Watch for early signs of hypersensitivity reactions such as rash and fever, and seek medical attention promptly.

Regular follow-up visits to evaluate seizure control and adverse reactions.